34 results on '"Gamba T"'
Search Results
2. Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020
- Author
-
Paratore, C., Zichi, C., Audisio, M., Bungaro, M., Caglio, A., Di Liello, R., Gamba, T., Gargiulo, P., Mariniello, A., Reale, M.L., Perrone, F., and Di Maio, M.
- Published
- 2022
- Full Text
- View/download PDF
3. 1444P Cancer diagnosis communication: The perspective of oncologists, patients and caregivers
- Author
-
Paratore, C., primary, Pacchiana Parravicini, M.V., additional, Cantale, O., additional, Carfì, F., additional, Zichi, C., additional, Gamba, T., additional, Pignataro, D., additional, Samuelly, A., additional, Tucci, M., additional, Di Maio, M., additional, and Novello, S., additional
- Published
- 2022
- Full Text
- View/download PDF
4. 1626P Time trends (2012-2016 vs 2017-2021) in health-related quality of life (QoL) assessment and reporting in oncology: A systematic review of randomized phase III trials
- Author
-
Marandino, L., primary, Trastu, F., additional, Ghisoni, E., additional, Lombardi, P., additional, Mariniello, A., additional, Reale, M.L., additional, Aimar, G., additional, Audisio, M., additional, Bungaro, M., additional, Caglio, A., additional, Di Liello, R., additional, Gamba, T., additional, Gargiulo, P., additional, Paratore, C., additional, Rossi, A., additional, Tuninetti, V., additional, Turco, F., additional, Perrone, F., additional, and Di Maio, M., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Patient-reported financial toxicity within the Italian public healthcare system: a single center cross-sectional analysis in patients with cancer
- Author
-
De Vita, F., primary, Greco, G., additional, Sperti, E., additional, Zichi, C., additional, Caglio, A., additional, Gamba, T., additional, Paparo, J., additional, Salerno, F., additional, Lacidogna, G., additional, Dionisio, R., additional, Marino, D., additional, Vignani, F., additional, Spanu, P. G., additional, Bellezza, A., additional, Fusco, L., additional, Polimeno, L., additional, Ariu, V., additional, Terzolo, S., additional, Perrone, F., additional, and Di Maio, L., additional
- Published
- 2022
- Full Text
- View/download PDF
6. IMPACT OF DIFFERENT DOSING STRATEGIES OF NIVOLUMAB IN PATIENTS WITH SOLID TUMORS: ITALIAN SINGLE CENTER ANALYSIS
- Author
-
Gamba, T., primary, Caglio, A., additional, Sacchi, F., additional, Paratore, C., additional, Fazzina, G., additional, Tagini, V., additional, Bellero, M., additional, Masucci, S., additional, Vignani, F., additional, Lacidogna, G., additional, Zichi, C., additional, Aimar, G., additional, Marino, D., additional, Sperti, E., additional, Gasco, A., additional, and Di Maio, M., additional
- Published
- 2021
- Full Text
- View/download PDF
7. 1715P Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
- Author
-
Rossi, A., Aimar, G., Audisio, M., Bungaro, M., Caglio, A., Di Liello, R., Gamba, T., Gargiulo, P., Ghisoni, E., Lombardi, P., Marandino, L., Mariniello, A., Paratore, C., Reale, M.L., Trastu, F., Tuninetti, V., Turco, F., Fabi, A., Perrone, F., and Di Maio, M.
- Published
- 2023
- Full Text
- View/download PDF
8. 800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy
- Author
-
Vignani, F., primary, Hamzaj, A., additional, De Giorgi, U., additional, Tambaro, R., additional, Basso, U., additional, Gamba, T., additional, Ermacora, P., additional, Santini, D., additional, Capacci, S., additional, Casadei, C., additional, Pignata, S., additional, Bimbatti, D., additional, Giannatempo, P., additional, Atzori, F., additional, Cavanna, L., additional, Veccia, A., additional, Scandurra, G., additional, Doni, L., additional, Aieta, M., additional, and Di Maio, M., additional
- Published
- 2020
- Full Text
- View/download PDF
9. 674P Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review
- Author
-
Marandino, L., primary, Buttigliero, C., additional, Vignani, F., additional, Gamba, T., additional, Necchi, A., additional, Tucci, M., additional, and Di Maio, M., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Evaluation of cone beam computed tomography and periapical radiography in the diagnosis of root resorption.
- Author
-
Lima, TF, Gamba, TO, Zaia, AA, Soares, AJ, Lima, T F, Gamba, T O, Zaia, A A, and Soares, A J
- Subjects
CONE beam computed tomography ,ROOT resorption (Teeth) ,PERIAPICAL diseases ,DENTAL pulp cavities ,ENDODONTICS - Abstract
Background: This study aimed to evaluate the accuracy of cone beam computed tomography (CBCT) and periapical radiography in diagnosing root resorption and verify the influence of filling material in detecting these lesions.Methods: Digital periapical radiographs and CBCT images of patients with root resorption and a history of dental trauma from a radiology clinic were reviewed retrospectively. The sample comprised 40 teeth with root resorption and 20 normal teeth as controls. Images were analysed by two radiologists and two endodontists. The sensitivity, specificity and accuracy were determined. The kappa coefficient assessed interobserver agreement and the t test determined significant differences between the imaging methods.Results: The accuracy of CBCT in diagnosing external (P = 0.0144) and internal (P = 0.0038) inflammatory resorption was significantly higher than for periapical radiography. For replacement resorption, no statistical difference was noted (P > 0.05). In endodontically treated teeth, CBCT was statistically superior in diagnosing root resorption (P = 0.0138).Conclusions: CBCT was superior to digital periapical radiography in diagnosing external and internal inflammatory root resorption after dental trauma and can be considered in the differential diagnosis of resorptive lesions in teeth with endodontic treatment. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
11. 3.1. Mandibular sexual dimorphism analysis in CBCT scans of a Brazilian population
- Author
-
De Oliveira Gamba, T., primary, Corrêa Alves, M., additional, and Haiter-Neto, F., additional
- Published
- 2014
- Full Text
- View/download PDF
12. Magnetic resonance imaging of the temporomandibular joint acquired using different parameters
- Author
-
Alonso, M., additional, Gamba, T., additional, Lopes, S., additional, Cruz, A., additional, Freitas, D., additional, and Haiter-Neto, F., additional
- Published
- 2014
- Full Text
- View/download PDF
13. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions.
- Author
-
Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A, Camerlingo, Massimo, Salvi, Pietro, Belloni, Giorgio, Gamba, Tiziano, Cesana, Bruno Mario, and Mamoli, Angelo
- Published
- 2005
- Full Text
- View/download PDF
14. Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review
- Author
-
Massimo Di Maio, Consuelo Buttigliero, Teresa Gamba, Laura Marandino, Francesca Vignani, Marcello Tucci, Andrea Necchi, Marandino, L., Vignani, F., Buttigliero, C., Gamba, T., Necchi, A., Tucci, M., and Di Maio, M.
- Subjects
Cancer Research ,medicine.medical_specialty ,Darolutamide ,Review ,lcsh:RC254-282 ,law.invention ,Androgen deprivation therapy ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Randomized controlled trial ,law ,abiraterone ,Internal medicine ,Apalutamide ,Enzalutamide ,Medicine ,030212 general & internal medicine ,Abiraterone ,apalutamide ,cognitive function ,enzalutamide ,business.industry ,darolutamide ,Cognition ,prostate cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Cognitive function ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Hormonal therapy ,business - Abstract
Simple Summary In patients with prostate cancer, the use of new-generation hormonal therapy, added to androgen deprivation therapy, requires careful evaluation of cognitive function. The aim of this systematic review is to describe the evidence about cognitive function in randomized trials testing new-generation hormonal therapy (abiraterone, enzalutamide, apalutamide, darolutamide). For each trial, we assessed the availability of both investigator-assessed cognitive impairment and disorders and patient-reported evaluation of cognitive function. Out of 19 trials, the investigator-based evaluation of cognitive impairment was available in seven (36.8%), while patient-reported evaluation of cognitive function results was presented only in one trial (5.3%). This analysis shows that, despite cognitive deterioration could be relevant in patients with prostate cancer, clinical development of new-generation hormonal drugs has not included a systematic evaluation of cognitive function. Abstract In patients with prostate cancer, earlier use and longer duration of new-generation hormonal therapy (NGHT), added to androgen deprivation therapy, requires careful evaluation of cognitive function. The aim of this systematic review is to describe the evidence about cognitive function in all the randomized trials (RCTs) testing NGHT (abiraterone, enzalutamide, apalutamide, darolutamide). We assessed the availability of both investigator-assessed cognitive impairment and disorders and patient-reported evaluation of cognitive function. Nineteen RCTs (17,617 patients) were included. The investigator-based evaluation of cognitive impairment was available in seven RCTs (36.8%). In total, 19/19 RCTs (100%) included patient-reported outcomes (PROs) collection, but PRO tools adopted allowed evaluation of cognitive function in two RCTs (10.5%). Among them, PRO-based cognitive function results were presented only in one RCT (5.3%): in ENZAMET, mean changes from baseline were worse with enzalutamide than with placebo, but deterioration-free survival favored enzalutamide. Despite cognitive deterioration could be relevant, clinical development of NGHT has not included a systematic evaluation of cognitive function. Assessment by investigators is at risk of underreporting, and commonly used PROs do not allow proper cognitive function analysis. Furthermore, the methodology of analysis can jeopardize the interpretation of results. Although direct comparisons are scanty, there could be differences between different NGHTs.
- Published
- 2020
15. Impact of CBCT acquisition protocols and artifact reduction filters on diagnosing vertical root fractures.
- Author
-
Hilgert EA, Liedke GS, da Silveira Tiecher PF, Arus NA, de Oliveira Gamba T, da Silveira HLD, and Vizzotto MB
- Abstract
Aim: To evaluate the impact of acquisition protocols and artifact reduction filters in cone beam computed tomography on diagnosing vertical root fractures in endodontically treated teeth with and without intraradicular posts., Materials and Methods: We analyzed 480 tomographic images acquired from two J. Morita scanners (0.125- and 0.08-mm voxel sizes protocols), with application of a blooming artifact reduction filter. Three evaluators assessed these images for root fractures using a 5-point Likert scale. Diagnostic accuracy between filters and protocols was determined using generalized linear models with binomial distribution for the outcome, considering protocol, filter, and dental status. Sensitivity, specificity, positive predictive value, and negative predictive value were also estimated for the filters and protocols., Results: The 0.08-mm voxel size protocol demonstrated a significantly higher percentage of accurate diagnosis compared to the 0.125-mm protocol (p = .001). No statistically significant differences (p ≥ .087) were observed for filter application, interaction between protocol and filter, or dental status. Accuracy, sensitivity, and specificity values were respectively: .93, .87, 1.00 (protocol 1); .99, .99, .99 (protocol 2); .98, .96, .99 (no filter); .95, .90, 1.00 (with filter)., Conclusion: The new findings found for the two J Morita scanners used in our study were that images acquired using the voxel size of 0.08 mm showed an improvement in the diagnosis of root fractures and the filters in these devices have no relevance significant for the diagnosis., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
16. Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study.
- Author
-
Fratino L, Polesel J, Giunta EF, Maruzzo M, Buti S, Hassan MA, Basso U, Rebuzzi SE, De Giorgi U, Cinausero M, Lipari H, Gamba T, Bimbatti D, Dri A, Ermacora P, Vignani F, Fornarini G, Rescigno P, and Banna GL
- Subjects
- Aged, Humans, Male, Caregivers psychology, Prospective Studies, Self Report, Activities of Daily Living, Prostatic Neoplasms
- Abstract
Instrumental activities of daily living (IADL) are significant health indicators closely related to executive functions and able to detect mild cognitive impairment. A decline in IADL usually precedes ADL limitation, including taking medications, and may therefore predict a cognitive decline. We aimed to investigate the association of patients' IADL score with other clinical factors, with a particular focus on the presence of a caregiver, and the impact on adherence to androgen receptor pathway inhibitors (ARPIs) and survival outcomes within the Meet-URO 5-ADHERE study. It was a large prospective multicentre observational cohort study monitoring adherence to ARPIs in 234 metastatic castrate-resistant PC (mCRPC) patients aged ≥ 70. We observed an association between impaired IADL and lower geriatric G8 scores (p < 0.01), and lower adherence to ARPIs whether assessed by pill counting (p = 0.01) or self-reported by the patient himself (p = 0.03). The combination of an IADL < 6 and the absence of a caregiver resulted in a significantly high risk of non-adherence to the ARPIs at the multivariable analysis (HR 9.23, 95% confidence interval 2.28-37.43, p = 0.01). IADL alongside the geriatric G8 scales represent essential tools to identify frail and less auto-sufficient patients who are extremely vulnerable particularly if not supported by a caregiver and have the highest risk of nonadherence to ARPIs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
- Author
-
Gamba T, Paparo J, Panepinto O, Dionisio R, Di Maio M, and Vignani F
- Subjects
- Female, Humans, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Ribose therapeutic use, Ovarian Neoplasms drug therapy, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms drug therapy
- Abstract
Poly ADP-ribose polymerase inhibitors (PARPis) have clinical activity in several cancers. The rationale of their therapeutic use in urothelial cancer (UC) resides in the high homologous-recombination repair (HRR) deficiency (HRD) prevalence and potential cross-sensitivity with platinum-based chemotherapy (PBCT). This review aims to summarize and analyze trials exploring the activity of PARPis in UC, focusing on patients who may benefit from those agents, the best clinical setting for the treatment and the benefit of the association with immune-checkpoint inhibitors (ICIs). We included all the available trials analyzing the activity of PARPis in UC in neoadjuvant, adjuvant, first or subsequent lines, and maintenance setting. We included PARPis in monotherapy and in association with other agents. The results in the maintenance setting are intriguing: ATLANTIS trial showed signals of improved progression-free survival in patients with known HRR aberrations, although the Meet-URO12 trial, with its negative results, suggested the failure of clinical selection based on platinum sensitivity only. Single-agent PARPis in pretreated patients showed discouraging results in an unselected population of chemo-refractory patients. Concerning the association of PARPis with ICIs, several trials are exploring their role in platinum-naïve setting; the results in the advanced setting were globally negative. Prior selection of HRD status is essential to identify patients who might benefit from PARPis. The ideal clinical settings seem to be the maintenance treatment and the combination with ICIs in platinum-naïve patients. Definitive results of ongoing and further trials will delineate the position for PARPis, if any, in UC therapy., Competing Interests: Disclosure All authors declare no support from any organization for the submitted work; MDM reports honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, GlaxoSmithKline, Amgen, Merck, Takeda for consultancy or participation to advisory boards and direct research funding from Tesaro/GlaxoSmithKline, institutional funding for work in clinical trials/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche; other authors declare no conflicts of interest that could appear to have influenced the submitted work., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals.
- Author
-
Breno M, Noris M, Rubis N, Parvanova AI, Martinetti D, Gamba S, Liguori L, Mele C, Piras R, Orisio S, Valoti E, Alberti M, Diadei O, Bresin E, Rigoldi M, Prandini S, Gamba T, Stucchi N, Carrara F, Daina E, Benigni A, and Remuzzi G
- Abstract
Large GWAS indicated that genetic factors influence the response to SARS-CoV-2. However, sex, age, concomitant diseases, differences in ancestry, and uneven exposure to the virus impacted the interpretation of data. We aimed to perform a GWAS of COVID-19 outcome in a homogeneous population who experienced a high exposure to the virus and with a known infection status. We recruited inhabitants of Bergamo province-that in spring 2020 was the epicenter of the SARS-Cov-2 pandemic in Europe-via an online questionnaire followed by personal interviews. Cases and controls were matched by age, sex and risk factors. We genotyped 1195 individuals and replicated the association at the 3p21.31 locus with severity, but with a stronger effect size that further increased in gravely ill patients. Transcriptome-wide association study highlighted eQTLs for LZTFL1 and CCR9 . We also identified 17 loci not previously reported, suggestive for an association with either COVID-19 severity or susceptibility., Competing Interests: The authors declare no competing interests., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
19. Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.
- Author
-
Rossi A, Aimar G, Audisio M, Bungaro M, Caglio A, Di Liello R, Gamba T, Gargiulo P, Ghisoni E, Lombardi P, Marandino L, Mariniello A, Paratore C, Reale ML, Trastu F, Tuninetti V, Turco F, Fabi A, Perrone F, and Di Maio M
- Subjects
- Humans, Medical Oncology, Randomized Controlled Trials as Topic, Neoplasms therapy
- Abstract
Introduction: Randomised controlled trials (RCTs) are usually considered the highest level of evidence for clinical practice. Patients assigned to control arm in RCTs should always receive the best available treatments to protect participants while also allowing for proper interpretation and applicability of study results. Here we analysed RCTs published in oncology between 2017 and 2021 to describe the frequency of suboptimal control arms., Methods: We identified phase III studies testing active treatments in patients with solid tumours among 11 major oncology journals. Each control arm was analysed, and the standard of care was determined according to international guidelines and scientific evidence at accrual beginning and until accrual completion. We identified studies with suboptimal control arm from the beginning (type 1) and studies with an initially optimal control arm which became outdated during the accrual period (type 2)., Results: This analysis included 387 studies. Forty-three (11.1%) control arms were judged as suboptimal: 24 (6.2%) type 1 and 19 (4.9%) type 2. These rates were higher in industry-sponsored compared to academic trials: 9.3% versus 1.9% for type 1 (p = 0.003); 7.9% versus 0.6% for type 2 (p = 0.001). Rates of suboptimal control arms were higher in studies with positive results: 8.1% versus 4.0% for type 1 (p = 0.09); 7.6% versus 1.7% for type 2 (p = 0.007)., Conclusions: Many trials have suboptimal control arms, even in journals with high-impact factors, leading to suboptimal treatment of control patients and biased evaluation of trial results., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper, RDL reports honoraria from Astellas Pharma and Janssen. LM reports honoraria from Gilead and Merck; research grant from AstraZeneca; travel expenses from Janssen. CP reports support for attending meetings and/or travel from Eli Lilly and Takeda; institutional research grant from IQVIA. MLR reports honoraria from Eli Lilly, AstraZeneca and Janssen. AF reports honoraria from Roche, Pfizer, Novartis, Dompè , Astra Zeneca, Seagen, Gilead, Exact Science, Eli Lilly; support for attending meetings and/or travel from Roche, Pfizer, Novartis, Dompè , Astra Zeneca, Seagen, Gilead, Exact Science, Eli Lilly; participation on advisory boards for Roche, Pfizer, Novartis, Astra Zeneca, Seagen, Gilead, Eli Lilly. FP reports honoraria from Bayer, Pierre Fabre, AstraZeneca, Incyte, Ipsen, Clovis, Astellas, Sanofi, Roche, Pfizer; institutional funding for work in clinical trials/contracted research from Roche, Bayer, AstraZeneca, Pfizer, Incyte, Tesaro/GlaxoSmithKline and Merck. MDM reports honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, Takeda for consultancy or participation to advisory boards institutional research funding from Tesaro/GlaxoSmithKline, institutional funding for work in clinical trials/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche. Other authors declare no relationships or activities that could appear to have influenced the submitted work., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network.
- Author
-
Giunta EF, De Padova S, Anpalakhan S, De Giorgi U, Maruzzo M, Rebuzzi SE, Cinausero M, Fratino L, Lipari H, Gamba T, Bimbatti D, Dri A, Ermacora P, Vignani F, Basso U, Buti S, Gandini A, Cremante M, Fornarini G, Rescigno P, and Banna GL
- Subjects
- Male, Humans, Aged, Prospective Studies, Caregivers, Prognosis, Nitriles therapeutic use, Treatment Outcome, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant pathology
- Abstract
Purpose: To assess caregivers' characteristics and influence of the presence or absence of the caregiver on clinical outcomes of older (≥70 years) metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (ABI) or enzalutamide (ENZ)., Methods: Patients from the Meet-URO 5 ADHERE study were assessed with a 5-item caregiver evaluation questionnaire focusing on the presence, age, degree of kinship, working status and qualification of the caregiver. We investigated the association between the presence of a caregiver and the clinical characteristics and outcomes of enrolled patients., Results: No differences were found in the main clinical characteristics between patients with or without a caregiver, except for a lower median G8 score (p = 0.0453) in the caregiver group. A longer radiographic PFS (rPFS) was observed in the group without a caregiver, with a trend towards more prolonged overall survival (OS) in the same group., Conclusion: Our work suggests a detrimental effect of caregivers in managing older mCRPC patients treated with ABI or ENZ, especially those identified as frail by the geriatric G8 screening score. Further work is needed to identify and address patients' vulnerability areas, which could have a detrimental effect on prognosis., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
21. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
- Author
-
Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, Stellato M, Atzori F, Aieta M, Masini C, Hamzaj A, Ermacora P, Veccia A, Scandurra G, Gamba T, Ignazzi G, Pignata S, Di Napoli M, Lolli C, Procopio G, Pierantoni F, Zonno A, Santini D, and Di Maio M
- Subjects
- Humans, Aged, Platinum therapeutic use, Progression-Free Survival, Disease Progression, Antineoplastic Combined Chemotherapy Protocols adverse effects, Maintenance Chemotherapy, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: Platinum-based chemotherapy (PBCT) is the standard first-line treatment for advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized between platinum drugs and poly-ADP ribose-polymerase (PARP) inhibitors., Objective: To compare maintenance treatment with the PARP inhibitor niraparib plus best supportive care (BSC) versus BSC alone in patients with advanced UC without disease progression after first-line PBCT., Design, Setting, and Participants: Meet-URO12 is a randomized, multicenter, open-label phase 2 trial. Patients with advanced UC, without disease progression after four to six cycles of PBCT, with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled between August 2019 and March 2021. Randomization was stratified by ECOG performance status (0/1) and response to PBCT (objective response/stable disease)., Intervention: Patients were randomized (2:1) to experimental arm A (niraparib 300 or 200 mg daily according to body weight and baseline platelets, plus BSC) or control arm B (BSC alone)., Outcome Measurements and Statistical Analysis: The primary endpoint was progression-free survival (PFS). The analysis was performed on an intention-to-treat basis. The secondary endpoints reported in this primary analysis are progression-free rate at 6 mo and safety (adverse event rate)., Results and Limitations: Fifty-eight patients were randomized (39 in arm A and 19 in arm B). The median age was 69 yr, ECOG performance status was 0 in 66% and 1 in 34%; and the best response with chemotherapy was objective response in 55% and stable disease in 45%. The median PFS was 2.1 mo in arm A and 2.4 mo in arm B (hazard ratio 0.92; 95% confidence interval 0.49-1.75, p = 0.81). The 6-mo progression-free rates were 28.2% and 26.3%, respectively. The most common adverse events with niraparib were anemia (50%, grade [G]3 11%), thrombocytopenia (37%, G3-4 16%), neutropenia (21%, G3 5%), fatigue (32%, G3 16%), constipation (32%, G3 3%), mucositis (13%, G3 3%), and nausea (13%, G3 3%). The main limitation of the study is the small sample size: in March 2021, approval of maintenance avelumab for the same setting rendered randomization of patients in the control arm to BSC alone unethical, and accrual was stopped prematurely., Conclusions: Addition of maintenance niraparib to BSC after first-line PBCT did not demonstrate a significant improvement in PFS in patients with UC. These results do not support the conduction of a phase 3 trial with single agent niraparib in this population., Patient Summary: In this trial, we tested the efficacy of niraparib as maintenance treatment in patients affected by advanced urothelial cancer after the completion of first-line chemotherapy. We could not demonstrate a significant improvement in progression-free survival with maintenance niraparib., (Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
22. Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network.
- Author
-
Rescigno P, Maruzzo M, Rebuzzi SE, Murianni V, Cinausero M, Lipari H, Fratino L, Gamba T, De Giorgi U, Caffo O, Bimbatti D, Dri A, Mosca A, Giunta EF, Ermacora P, Vignani F, Msaki A, Bonifacio B, Lombardo V, Conteduca V, Basso U, Fornarini G, and Banna GL
- Subjects
- Humans, Male, Aged, Aged, 80 and over, Prospective Studies, Prostatic Neoplasms drug therapy
- Abstract
Background: Novel androgen receptor signaling inhibitors for prostate cancer (PC) impose the burden of self-administration on older patients overwhelmed by the requirement of many other concomitant medications., Patients and Methods: This study evaluated the proportion of non-adherence in a 12-month follow-up period and the first 3 months to abiraterone (ABI) or enzalutamide (ENZ). In a prospective multicenter observational cohort study, patients with metastatic castration-resistant PC (mCRPC) aged ≥70 years receiving ABI or ENZ pre- or post-docetaxel were enrolled. Treatment monitoring included pill counting, a self-assessment questionnaire, and clinical diaries at each clinical visit. Non-adherence rates were based on proportions of missed/prescribed pills ratios by pill counting., Results: Overall, 234 patients were recruited with median age of 78 years (range, 73-82); 86 (37%) were treated with ABI, and 148 (63%) with ENZ. The median follow-up for adherence was seven monthly cycles (IQR: 4-12). The two cohorts were well balanced for baseline characteristics. The percentage of non-adherence by pill counting was slightly higher for ABI than ENZ (5.2% vs. 4.2%, P < .001). By self-reporting, patients on ENZ tended to report more frequently than those with ABI forgetfulness as the reason for missing events (42% vs. 17%, P < .001). A lower Geriatric G8 score correlated with non-adherence (P = .004). Overall survival (OS) was 48.8 months. Patients on ABI had radiographic progression-free survival (rPFS) of 28.4 [24.2-32.5], while for ENZ patients, we reported a median rPFS of 23.1 [18.2-28.1] months., Conclusion: Physicians tend to treat older mCRPC patients with ENZ. Non-adherence rate is relatively low overall but can be higher with ABI than with ENZ and correlates with the Geriatric G8 score. Forgetfulness is a potential barrier for ENZ., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2022
- Full Text
- View/download PDF
23. The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network.
- Author
-
Banna GL, Basso U, Giunta EF, Fratino L, Rebuzzi SE, Buti S, Maruzzo M, De Giorgi U, Murianni V, Cinausero M, Lipari H, Gamba T, Caffo O, Bimbatti D, Dri A, Mosca A, Ermacora P, Vignani F, Msaki A, Bonifacio B, Lombardo V, Conteduca V, Fornarini G, and Rescigno P
- Subjects
- Male, Humans, Aged, Aged, 80 and over, Prospective Studies, Prostate-Specific Antigen, Receptors, Androgen, Treatment Outcome, Prostatic Neoplasms, Castration-Resistant drug therapy
- Abstract
Introduction: Androgen receptor pathway inhibitors (ARPIs) have been increasingly offered to older patients with prostate cancer (PC). However, prognostic factors relevant to their outcome with ARPIs are still little investigated. Methods and Materials: The Meet-URO network ADHERE was a prospective multicentre observational cohort study evaluating and monitoring adherence to ARPIs metastatic castrate-resistant PC (mCRPC) patients aged ≥70. Cox regression univariable and multivariable analyses for radiographic progression-free (rPFS) and overall survival (OS) were performed. Unsupervised median values and literature-based thresholds where available were used as cut-offs for quantitative variables. Results: Overall, 234 patients were enrolled with a median age of 78 years (73-82); 86 were treated with abiraterone (ABI) and 148 with enzalutamide (ENZ). With a median follow-up of 15.4 months (mo.), the median rPFS was 26.0 mo. (95% CI, 22.8-29.3) and OS 48.8 mo. (95% CI, 36.8-60.8). At the MVA, independent prognostic factors for both worse rPFS and OS were Geriatric G8 assessment ≤ 14 ( p < 0.001 and p = 0.004) and PSA decline ≥50% ( p < 0.001 for both); time to castration resistance ≥ 31 mo. and setting of treatment (i.e., post-ABI/ENZ) for rPFS only ( p < 0.001 and p = 0.01, respectively); age ≥78 years for OS only ( p = 0.008). Conclusions: Baseline G8 screening is recommended for mCRPC patients aged ≥70 to optimise ARPIs in vulnerable individuals, including early introduction of palliative care.
- Published
- 2022
- Full Text
- View/download PDF
24. What is the accuracy of the surgical guide in the planning of orthognathic surgeries? A systematic review.
- Author
-
Goulart ME, Biegelmeyer TC, Moreira-Souza L, Adami CR, Deon F, Flores IL, and Gamba TO
- Subjects
- Computer-Aided Design, Humans, Imaging, Three-Dimensional, Printing, Three-Dimensional, Orthognathic Surgery, Orthognathic Surgical Procedures methods, Surgery, Computer-Assisted methods
- Abstract
Background: To investigate the true accuracy of the surgical guide in the planning of orthognathic surgeries, which are performed worldwide., Material and Methods: A systematic search was conducted in the PubMed database, Web of science, Scopus and Embase, covering August 2020 to January 2021. Studies that included patients with dentofacial deformity including anteroposterior, vertical and asymmetry problems who were undergoing an orthognathic surgery procedure were included; QUADAS-2 was used to determine the risk of bias by analyzing the quality of the studies. A PRISMA (flowchart) was created to show the study selection, keywords, nomination processes, and inclusion and exclusion criteria., Results: Eleven studies were selected for qualitative and quantitative synthesis. All studies evaluated described high precision of the surgical guide, where the lowest error values were represented by the CAD/CAM technique., Conclusions: The planning and printing errors related to the guide were all less than 2 mm, and the absolute averages of the errors related to virtual planning in the analysis of the different plans were less than 1 mm. Finally, the measurement of the ANB angle obtained equivalent results between the virtual planning and the traditional.
- Published
- 2022
- Full Text
- View/download PDF
25. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
- Author
-
Zichi C, Paratore C, Gargiulo P, Mariniello A, Reale ML, Audisio M, Bungaro M, Caglio A, Gamba T, Perrone F, and Di Maio M
- Subjects
- Humans, Neoplasms mortality, Progression-Free Survival, Time Factors, Clinical Trials, Phase III as Topic, Endpoint Determination, Neoplasms therapy, Randomized Controlled Trials as Topic, Research Design
- Abstract
Background and Aim: Trial designs using multiple primary endpoints (MPEs) are increasing in phase III cancer trials. Our objectives were to describe the incidence of MPEs in recently published phase III trials testing systemic treatments in patients with advanced cancer; the main characteristics of trials adopting MPEs; the presence of mature results for all endpoints in the primary publication; consistency between results of each endpoint and authors' conclusions., Methods: Articles of randomised phase III trials conducted in patients with advanced cancer, published between 2017 and 2020, were retrieved from PubMed. The main outcome was the proportion of trials with MPEs. In principle, according to regulatory agencies, we considered two distinct cases: (i) MPEs correspond to 'multiple chances' for the success of experimental treatment, needing adjustment for multiplicity, and (ii) a positive result depends on the success in all MPEs ('co-primary' endpoints)., Results: Out of 235 eligible trials, 27 trials (12%) adopted MPE, mostly overall survival (OS) and progression-free survival (PFS). The proportion of trials with MPEs increased over time, from 6% in 2017 to 20% in 2020 (p = 0.025). MPEs were adopted in 16% of for-profit trials versus 4% of non-profit trials (p = 0.006). The proportion of trials adopting MPEs was particularly high with immunotherapy (53%, p < 0.00001). Out of 27 trials with MPEs, 10 (37%) adopted an explicit definition of 'co-primary' endpoints, but only 1/10 declared the positivity of both endpoints critical for interpretation. Most trials (23, 85%) planned correction for multiplicity. Of 21 publications with positive conclusions, only 12 had a statistically significant positive result in both primary endpoints. In four cases (15%), positive conclusions were based on PFS results alone., Conclusions: Adoption of MPEs in randomised trials in oncology is quite common. Only a minority of trials respect recommendations by regulatory agencies about the adoption of MPEs, definition of 'co-primary' endpoints and correction for multiplicity., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships that may be considered as potential competing interests: Maria Lucia Reale had a role as a consultant for Eli-Lilly, outside the submitted work. Francesco Perrone reports grants, personal fees and non-financial support from Bayer, personal fees from Sandoz, grants and personal fees from Incyte, personal fees from Celgene, grants and personal fees from Astra Zeneca, personal fees from Pierre Fabre, personal fees from Janssen Cilag, grants from Roche, grants from Pfizer, outside the submitted work.Massimo Di Maio received honoraria and had roles as consultant or advisor for AstraZeneca, Pfizer, Novartis, Roche, Takeda, Eisai, Janssen, Astellas; received institutional research grant by Tesaro – GlaxoSmithKline, outside the submitted work. All remaining authors declared no conflicts of interest., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
26. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
- Author
-
Aimar G, Paratore C, Zichi C, Marino D, Sperti E, Caglio A, Gamba T, De Vita F, and Di Maio M
- Abstract
Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identification of distinct molecular alterations with corresponding targeted therapies is modifying this therapeutic algorithm. The aim of this review is to present an overview of targeted therapy for BTCs, describing published available data and potential future challenges in ongoing trials. From clinicaltrials.gov online database all ongoing trials for BTCs (any stage) was examinated in July 2021, and data regarding study design, disease characteristics and type of treatments were registered. Oncogenic-driven therapy (targeted therapy) was investigated in 67 trials. According to research, 15 ongoing trials (22.4%) are investigating fibroblast growth factor (FGF) receptor (FGFR)-inhibitors in BTCs. Three (18.7%) are open-label randomized multicenter phase 3 trials, 8 (50%) are single-arm phase two trials, and 4 (25%) are phase one studies. Twelve (17.9%) clinical trials dealt with isocitrate dehydrogenase (IDH) 1/2 targeting therapy either in combination with cisplatin (Cis) and gemcitabine (Gem) as first-line treatment for BTCs or in monotherapy in patients with IDH1 mutant advanced malignancies, including cholangiocarcinoma (CCA). Nine (13.4%) clinical trials tested human epidermal growth factor receptor (HER) 2 targeting therapy. Four (44.4%) studies are phase I trials, two (22.2%) are phase I/II trials, and three (33.3%) phase II trials. Rare molecular alterations in BTCs, such as anaplastic lymphoma kinase (ALK), c-ros oncogene1 receptor tyrosine kinase (ROS1), and v-RAF murine sarcoma viral oncogene homologue B1 (BRAF), are also under investigation in a few trials. Forty-four clinical trials (17.2%) are investigating not oncogenic-driven multitarget therapy like multireceptor tyrosin kinase inhibitors and antiangiogenetic agents. In conclusion, this review shows that BTCs management is experiencing important innovations, especially in biomarker-based patient selection and in the new emerging therapeutic approach. Many ongoing trials could answer questions regarding the role of molecular inhibitors leading to new therapeutic frontiers for molecular subcategories of BTCs., Competing Interests: The authors declare the following financial interests/personal relationships that may be considered as potential competing interests: Massimo Di Maio received honoraria and had roles as consultant or advisor for AstraZeneca, Pfizer, Novartis, Roche, Takeda, Eisai, Janssen, Astellas; received institutional research grant by Tesaro e GlaxoSmithKline, outside the submitted work. All remaining authors declared no conflicts of interest., (© The Author(s) 2021.)
- Published
- 2021
- Full Text
- View/download PDF
27. Overexpression of ALDH1 and EMT marker profile are linked with unfavorable outcome in head and neck cancer.
- Author
-
Vieira V, Campos LH, Jesus LH, Klabunde C, Gamba TD, Flores IL, Oliveira MG, and Rados PV
- Subjects
- Aldehyde Dehydrogenase 1 Family, Biomarkers, Tumor, Epithelial-Mesenchymal Transition, Humans, Neoplasm Recurrence, Local, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Abstract
Background: The aim of this research was to assess the expression of aldehyde dehydrogenase 1 (ALDH1) and epithelial-mesenchymal transition (EMT) markers in head and neck squamous cell carcinoma (HNSCC), and to correlate them with the clinical and histopathological parameters of a patient cohort with follow-up over an 8-year period., Material and Methods: For this, seventeen HNSCC and non-neoplastic adjacent epithelium (AE) samples were subjected to laser microdissection and real-time PCR to evaluate the mRNA expression of ALDH1, E-cadherin (E-CAD), N-cadherin (N-CAD), and vimentin (VIM). Also, immunohistochemistry was performed for ALDH1, E-CAD, N-CAD, and VIM in the tumor center (TC), invasion front (IF), and AE of the seventeen samples. Mann-Whitney, Kruskal-Wallis and Chi-square tests were used to correlate the mRNA and immunohistochemical expression with different variables, considering p<0.05. Kaplan-Meier curves were produced for local recurrence, regional metastasis and treatment., Results: A mRNA overexpression of ALDH1 in primary tumors was associated with regional metastasis and a high ALDH1 immunostaining was related to metastasis and a worse patient outcome. Additionally, a favorable outcome was associated with the transition phase and an unfavorable outcome was associated with EMT event. An overall 26.9 months was observed with longer survival associated with surgery and radiotherapy., Conclusions: However, due to the intense variability inherent to the indicator proteins in the EMT process, the complete profile markers related to this biological process should be continuous investigated.
- Published
- 2020
- Full Text
- View/download PDF
28. Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review.
- Author
-
Marandino L, Vignani F, Buttigliero C, Gamba T, Necchi A, Tucci M, and Di Maio M
- Abstract
In patients with prostate cancer, earlier use and longer duration of new-generation hormonal therapy (NGHT), added to androgen deprivation therapy, requires careful evaluation of cognitive function. The aim of this systematic review is to describe the evidence about cognitive function in all the randomized trials (RCTs) testing NGHT (abiraterone, enzalutamide, apalutamide, darolutamide). We assessed the availability of both investigator-assessed cognitive impairment and disorders and patient-reported evaluation of cognitive function. Nineteen RCTs (17,617 patients) were included. The investigator-based evaluation of cognitive impairment was available in seven RCTs (36.8%). In total, 19/19 RCTs (100%) included patient-reported outcomes (PROs) collection, but PRO tools adopted allowed evaluation of cognitive function in two RCTs (10.5%). Among them, PRO-based cognitive function results were presented only in one RCT (5.3%): in ENZAMET, mean changes from baseline were worse with enzalutamide than with placebo, but deterioration-free survival favored enzalutamide. Despite cognitive deterioration could be relevant, clinical development of NGHT has not included a systematic evaluation of cognitive function. Assessment by investigators is at risk of underreporting, and commonly used PROs do not allow proper cognitive function analysis. Furthermore, the methodology of analysis can jeopardize the interpretation of results. Although direct comparisons are scanty, there could be differences between different NGHTs.
- Published
- 2020
- Full Text
- View/download PDF
29. Collapsing Lesions and Focal Segmental Glomerulosclerosis in Pregnancy: A Report of 3 Cases.
- Author
-
Orozco Guillén OA, Velazquez Silva RI, Gonzalez BM, Becerra Gamba T, Gutiérrez Marín A, Paredes NR, Cardona Pérez JA, Soto Abraham V, Piccoli GB, and Madero M
- Subjects
- Adult, Biopsy, Needle, Creatinine blood, Disease Progression, Female, Gestational Age, Glomerulosclerosis, Focal Segmental drug therapy, Humans, Immunohistochemistry, Kidney Function Tests, Postnatal Care, Pregnancy, Pregnancy Complications drug therapy, Prenatal Diagnosis methods, Proteinuria drug therapy, Risk Assessment, Sampling Studies, Young Adult, Glomerulosclerosis, Focal Segmental diagnosis, Immunosuppressive Agents therapeutic use, Kidney Glomerulus pathology, Pregnancy Complications physiopathology, Pregnancy Outcome, Proteinuria physiopathology
- Abstract
The relationship between focal segmental glomerulosclerosis (FSGS) and pregnancy is complex and not completely elucidated. Pregnancy in patients with FSGS poses a high risk for complications, possibly due to hemodynamic factors, imbalance between angiogenic and antiangiogenic factors, and hormonal conditioning. Although poor clinical outcomes associated with collapsing FSGS are common outside of pregnancy, the prognosis during pregnancy is not well documented. We report 3 patients who developed collapsing FSGS during pregnancy, 2 of whom had presumed underlying FSGS. Two patients underwent biopsy during pregnancy, and 1, during the puerperium. None of the 3 patients improved spontaneously after delivery, and 1 experienced a rapid deterioration in kidney function and proteinuria after delivery. Aggressive immunosuppressive therapy led to a full response in 1 case (without chronic lesions) and to partial responses in the remaining 2 cases. These cases suggest that collapsing lesions should be considered in patients with FSGS who develop a rapid increase in serum creatinine level or proteinuria during pregnancy and that these lesions may at least partially respond to treatment., (Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
30. Development and validation of a formula based on maxillary sinus measurements as a tool for sex estimation: a cone beam computed tomography study.
- Author
-
Farias Gomes A, de Oliveira Gamba T, Yamasaki MC, Groppo FC, Haiter Neto F, and Possobon RF
- Subjects
- Adult, Female, Forensic Sciences methods, Humans, Imaging, Three-Dimensional methods, Male, Cone-Beam Computed Tomography methods, Maxillary Sinus diagnostic imaging, Sex Determination Analysis methods
- Abstract
Background: As sex estimation is an important step to delineate the biological profile, the development of tools employing anatomical structures which may maintain their integrity even after extreme events, such as the maxillary sinus, become useful for forensic identification. Thus, the aim in the present study was to develop and validate a formula for sex estimation through measurements in the maxillary sinuses in a Brazilian population, using cone beam computed tomography (CBCT) scans., Material and Methods: Linear and volumetric measurements in the maxillary sinus were performed bilaterally in 94 CBCT scans from 45 males (mean age 25.2 ± 0.79) and 49 females (mean age 23.7 ± 0.50). The OnDemand 3D software was employed for linear measurements (height, length and width of, and the largest distance between the right and left maxillary sinuses), while the ITK-SNAP 3.0 segmentation software was used to acquire the volume. The data obtained was applied to a mathematical model for sex estimation. To validate the developed formula, another sample composed of 60 CBCT images of Brazilian individuals was tested., Results: Overall, maxillary sinuses' measurements were significantly higher in males, without statistically significant differences between the right and left sides within each group. The most dimorphic measurement was the height, with an accuracy of 77.7% regarding sex estimation. The formula created lead to a sex estimation of 87.8% for females and 80% for males, with an overall accuracy of 84%. When the formula validity was tested in another sample, it showed an accuracy of 82.4%., Conclusion: The formula developed through measurements in the maxillary sinus using CBCT scans showed an accuracy of 84% for sex estimation and can be applied as a complementary method for human identification in the Brazilian population.
- Published
- 2019
- Full Text
- View/download PDF
31. Aggressive unicystic ameloblastoma affecting the posterior mandible: late diagnosis during orthodontic treatment.
- Author
-
Pereira de Castro Lopes SL, Flores IL, de Oliveira Gamba T, Ferreira-Santos RI, Leonelli de Moraes ME, Alvarez Cabello A, and Nascimento Moutinho P
- Abstract
Maxillofacial images must be examined to find pathologies not identified during clinical examination. Unicystic ameloblastoma (UA) extending to the mandibular body and ramus was neglected on initial panoramic radiographic examination. After orthodontic therapy, a huge lesion was observed clinically and through imaging exams. After the conservative surgery, no recurrence was observed during five years of follow-up. This case emphasized the need for careful evaluation of patient images focusing on the oral diagnosis before any dental treatment planning, including orthodontic therapy., Competing Interests: Conflict of Interest: No potential conflict of interest relevant to this article was reported.
- Published
- 2017
- Full Text
- View/download PDF
32. Wound Healing Activity and Chemical Standardization of Eugenia pruniformis Cambess.
- Author
-
de Albuquerque RD, Perini JA, Machado DE, Angeli-Gamba T, Esteves RD, Santos MG, Oliveira AP, and Rocha L
- Abstract
Background: Eugenia pruniformis is an endemic species from Brazil. Eugenia genus has flavonoids as one of the remarkable chemical classes which are related to the improvement of the healing process., Aims: To evaluate of wound healing activity of E. pruniformis leaves and to identify and quantify its main flavonoids compounds., Materials and Methods: Wound excision model in rats was used to verify the hydroethanolic and ethyl acetate extracts potential. The animals were divided in four groups of six and the samples were evaluated until the 15° day of treatment. Hydroxyproline dosage and histological staining with hematoxilin-eosin and Sirius Red were used to observe the tissue organization and quantify the collagen deposition, respectively. Chemical compounds of the ethyl acetate extract were identified by chromatographic techniques and mass spectrometry analysis and total flavonoids content was determined by spectrophotometric method. The antioxidant activity was determined by oxygen radical absorbing capacity (ORAC) and 2,2-diphenyl-1-picrylhydrazylhydrate radical photometric (DPPH) assays., Results: The treated group with the ethyl acetate extract showed collagen deposition increase, higher levels of hidroxyproline, better tissue reorganization and complete remodeling of epidermis. Quercetin, kaempferol and hyperoside were identified as main compounds and flavonoids content value was 43% (w/w). The ORAC value of the ethyl acetate extract was 0.81± 0.05 mmol TE/g whereas the concentration to produce 50% reduction of the DPPH was 7.05± 0.09 μg/mL., Conclusion: The data indicate a wound healing and antioxidant activities of E. pruniformis . This study is the first report of flavonoids and wound healing activity of E. pruniformis ., Key Messages: Eugenia pruniformis extract accelerates wound healing in skin rat model, probably due to its involvement with the collagen deposition increase, higher levels of hidroxyproline, dermal remodelling and potent antioxidant activity. Chemical standardization of the active wound healing extract was done. The total flavonoid content was 43% (w/w) and quercetin, kaempferol and hyperoside were identified as main compounds., Summary: Wound excision model in rats showed the potential wound healing activity of E. pruniformis by collagen deposition increase, higher levels of hidroxyproline, better tissue reorganization and complete remodeling of epidermis.Flavonoids are the main compounds of the endemic E. pruniformis and quercetin, kaempferol and hyperoside were identified in ethyl acetate extract by TLC, HPLC-PDA and HRESI-MS analysis.The ethyl acetate extract of E. pruniformis showed a potent antioxidant activity by ORAC and DPPH assays Abbreviation used: NC: Negative control, PC: Positive control, CH: Crude hydroethanolic extract, EA: Ethyl acetate extract, TE: Trolox equivalent, mg: Milligram, mM: Millimolar, mL: Milliliter, HPLC-PDA: High performance liquid chromatography with a photodiode array detector, HRESI-MS: High-resolution electrospray ionization mass spectrometry analysis, TLC: Thin layer chromatography, ORAC: Oxygen radical absorbance capacity, w/v: Weight per volume.
- Published
- 2016
- Full Text
- View/download PDF
33. Utility of panoramic radiography for identification of the pubertal growth period.
- Author
-
Lopes LJ, de Oliveira Gamba T, Visconti MA, Ambrosano GM, Haiter-Neto F, and Freitas DQ
- Subjects
- Adolescent, Age Determination by Skeleton methods, Age Determination by Teeth methods, Amelogenesis physiology, Bicuspid diagnostic imaging, Bicuspid growth & development, Child, Cross-Sectional Studies, Cuspid diagnostic imaging, Cuspid growth & development, Dental Pulp diagnostic imaging, Dental Pulp growth & development, Dentinogenesis physiology, Female, Humans, Male, Molar diagnostic imaging, Molar growth & development, Sex Factors, Tooth Apex diagnostic imaging, Tooth Apex growth & development, Tooth Calcification physiology, Tooth Crown diagnostic imaging, Tooth Crown growth & development, Tooth Root diagnostic imaging, Tooth Root growth & development, Puberty physiology, Radiography, Panoramic statistics & numerical data
- Abstract
Introduction: Our aim in this study was to investigate the association between dental mineralization stages and the periods of the pubertal growth spurt (PGS)., Methods: The sample included panoramic and hand-wrist radiographs from 491 subjects (222 boys, 269 girls) aged 7 to 17 years. Dental development was rated, and skeletal maturation was evaluated. The relevant associations were investigated by analysis of ordinal multinomial logistic regression., Results: The second molar (odds ratio [OR] = 4.34) and the first premolar (OR = 2.45) were the best growth predictors for girls. For boys, the second molar (OR = 6.80), second premolar (OR = 2.41), and canine (OR = 3.21) proved to be the best predictors. Stages D and E of the second molar for girls, and stages E and F for boys, corresponded to the onset of the accelerated growth spurt. Stage F of the second molar for girls and stage G for boys corresponded to the peak of the PGS. At the end of the PGS, most teeth had already attained apical closure. In girls, however, most second molars were found at stage G., Conclusions: An association exists between the dental mineralization stages and the periods of the PGS, especially for second molars. Panoramic radiographs can be used as the first diagnostic tool to estimate the pubertal growth period., (Copyright © 2016 American Association of Orthodontists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
34. Topical application of Acheflan on rat skin injury accelerates wound healing: a histopathological, immunohistochemical and biochemical study.
- Author
-
Perini JA, Angeli-Gamba T, Alessandra-Perini J, Ferreira LC, Nasciutti LE, and Machado DE
- Subjects
- Animals, Immunohistochemistry, Rats, Rats, Wistar, Plant Extracts pharmacology, Skin drug effects, Skin injuries, Wound Healing drug effects
- Abstract
Background: Dermal wound healing involves a cascade of complex events including angiogenesis and extracellular matrix remodeling. Several groups have focused in the study of the skin wound healing activity of natural products. The phytomedicine Acheflan®, and its main active constituent is the oil from Cordia verbenacea which has known anti-inflammatory, analgesic and antimicrobial activities. To our knowledge, no investigation has evaluated the effect of Acheflan® in an experimental model of skin wound healing. The present study has explored the wound healing property of Acheflan® and has compared it with topical effectiveness of collagenase and fibrinolysin by using Wistar rat cutaneous excision wound model., Methods: Animals were divided into four groups: untreated animals are negative control (NC), wounds were treated topically every day with Collagenase ointment (TC), with Fibrinolysin ointment (TF) and with cream Acheflan (TAc). Skin samples were collected on zero, 8th and 15th days after wounding. The healing was assessed by hematoxylin-eosin (HE), picrosirius red, hydoxyproline content and immunohistochemical analysis of the vascular endothelial growth factor (VEGF) and matrix metalloprotease-9 (MMP-9). Statistical analysis was done by ANOVA and Student t-test (p < 0.05)., Results: The histological analysis HE of wound in the TAc group was more efficient because it was possible to observe the complete remodeling of the epidermis indicating the regression of lesions compared with the NC. The evaluation of picrosirius staining has demonstrated a significant increase of collagen distribution in the TC and TAc treatments compared with NC and TF groups. These results are corroborated with hydroxyproline content. Skin TC and TAc treated rats have showed an increase of VEGF and MMP-9 compared with NC and TF groups. All parameters were significant (P < 0.05)., Conclusion: The phytomedicine Acheflan® (oil of Cordia verbenacea) and TC possess higher therapeutic properties for wound healing compared with TF. These ointments seem to accelerate wound healing, probably due to their involvement with the increase of angiogenesis and dermal remodeling.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.